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Abstract
Background
Altered expression of transcription factor specificity protein 4 (SP4) has been found in the
postmortem brain of patients with psychiatric disorders including schizophrenia and bipolar
disorder. Reduced levels of SP4 protein have recently been reported in peripheral blood
mononuclear cells in first-episode psychosis. Also, SP4 levels are modulated by lithium
treatment in cultured neurons. Phosphorylation of SP4 at S770 is increased in the cerebel-
lum of bipolar disorder subjects and upon inhibition of NMDA receptor signaling in cultured
neurons. The aim of this study was to investigate whether SP4 S770 phosphorylation is in-
creased in lymphocytes of first-episode psychosis patients and the effect of lithium treat-
ment on this phosphorylation.
Methods
A cross-sectional study of S770 phosphorylation relative to total SP4 immunoreactivity
using specific antibodies in peripheral blood mononuclear cells in first-episode psychosis
patients (n = 14, treated with lithium or not) and matched healthy controls (n = 14) by immu-
noblot was designed. We also determined the effects of the prescribed drugs lithium, olan-
zapine or valproic acid on SP4 phosphorylation in rat primary cultured cerebellar granule
neurons.
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Results
We found that SP4 S770 phosphorylation was significantly increased in lymphocytes in
first-episode psychosis compared to controls and decreased in patients treated with lithium
compared to patients who did not receive lithium. Moreover, incubation with lithium but not
olanzapine or valproic acid reduced SP4 phosphorylation in rat cultured cerebellar granule
neurons.
Conclusions
The findings presented here indicate that SP4 S770 phosphorylation is increased in lym-
phocytes in first-episode psychosis which may be reduced by lithium treatment in patients.
Moreover, our study shows lithium treatment prevents this phosphorylation in vitro in neu-
rons. This pilot study suggests that S770 SP4 phosphorylation could be a peripheral bio-
marker of psychosis, and may be regulated by lithium treatment in first-episode psychosis.
Introduction
Increasing evidence indicates that transcription factor specificity protein 4 (SP4) may play a
role in major psychiatric disorders. SP4 is a zinc finger transcription factor that binds to G-C/T
rich sequences, regulating the expression of a large number of genes implicated in diverse bio-
logical functions [1]. SP4 is highly expressed in neurons and brain [2–4] and reduction of SP4
leads to defects in developmental dendrite patterning, hippocampal long-term potentiation,
and animal behaviors associated with psychiatric disorders, including deficits in contextual
and spatial memory and prepulse inhibition [5–8]. Genetic variations at the human SP4 locus
have been associated with bipolar disorder and schizophrenia [9, 10]. In addition, previous
studies have shown altered SP4 protein abundance in the postmortem cerebellum and prefron-
tal cortex both in bipolar disorder [11] and schizophrenia [12], as well as in the hippocampus
in schizophrenia [13]. Thus, these studies indicate that the regulation of SP4 protein levels and
function in the brain may be relevant to the pathophysiology of psychiatric disorders with
psychotic features.
Reduced N-Methyl-D-Aspartate (NMDA) receptor function has been proposed as one of
the main contributors to symptom emergence in schizophrenia [14–16]. NMDAR inhibition
modulates SP4 protein levels in the hippocampus in a pharmacological mouse model of acute
psychosis [13]. Inhibition of NMDA receptor signaling also promotes phosphorylation of SP4
protein at serine 770 (S770) in cerebellar granule neurons; this phosphorylation reduced Sp4
function independent of an effect on Sp4 levels [17]. Notably, relative levels of phosphoSp4
(pSp4) are increased in the postmortem cerebellum of bipolar disorder subjects and, in this
context, SP4 S770 phosphorylation and total SP4 immunoreactivity showed an inverse correla-
tion [18]. Moreover, we have also recently shown that relative abundance of pSP4 in the post-
mortem cerebellum of patients with schizophrenia directly associates with the severity of
negative symptoms [18]. A reduction in SP4 immunoreactivity in peripheral lymphocytes has
been reported in first-episode psychosis patients (FEP) [19]. In a more recent study, this lower
peripheral SP4 immunoreactivity in FEP has been shown to correlate positively with right hip-
pocampal volume, measured by voxel-based morphometric analysis on brain structural mag-
netic resonance images [20], thus suggesting a link between brain alterations found in this
disorder [21] and peripheral SP4 immunoreativity. However, whether SP4 phosphorylation is
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increased in early psychosis, and whether this correlates with reduced Sp4 levels in lympho-
cytes of FEP patients is not known.
SP4 levels are increased in cerebellar granule neurons upon treatment with the mood stabi-
lizer drug lithium [11]. As noted above, SP4 phosphorylation and protein abundance display
an inverse correlation in the cerebellum of bipolar disorder patients and in cerebellar granule
neurons under depolarizing or non-depolarizing conditions [17] suggesting that maybe lithium
could reduce SP4 phosphorylation. Lithium is an effective treatment for bipolar disorder from
the early phases of acute mania, the most efficient drug for long-term preventive treatment and
it also has an anti-suicidal effect [22, 23]. Therapeutic effects of lithium only become apparent
after weeks of treatment [24]; this delayed response suggests that lithium-dependent changes
in gene expression programs, perhaps some mediated by SP4, contribute to long-term cellular
remodeling.
Based on these previous observations, we hypothesized that SP4 S770 phosphorylation may
be altered in peripheral blood mononuclear cells in first-episode psychosis patients. The main
aim of this study was to investigate whether phosphorylation at SP4 S770 was increased in pe-
ripheral blood mononuclear cells in first-episode psychosis, how it related to SP4 protein abun-
dance, and if this phosphorylation could be modulated by treatment with lithium. To test this
possibility, we included a subgroup analysis based on the presence of lithium treatment in our
human sample. Moreover, to further explore the effect on SP4 S770 phosphorylation of lithium
and other prescribed drugs found in the FEP cohort, we tested the effect of lithium, valproic
acid, and olanzapine (the most prevalent antipsychotic in our cohort of FEP) in an in vitro cell
model.
Materials and Methods
Subjects and clinical assessments
Fourteen first-episode psychosis patients from the acute psychiatric ward of Parc Sanitari Sant
Joan de Deu and fourteen similar age-sex-healthy controls were recruited and evaluated in a
previously described study [19]. Inclusion criteria for patients were the presence of positive
psychotic symptoms such as hallucinations or delusions for no longer than 6 months, severe
enough to warrant admission to the Acute Inpatient Ward. The age at admission was between
17 and 40 years. Patients were recruited one week before discharge and evaluated by a trained
psychiatrist with Positive and Negative Syndrome Scale (PANSS), Young Mania Rating Scale
(YMRS) and Calgary Depression Scale for Schizophrenia (CDSS) as detailed previously [19]. A
group of healthy controls of comparable age and gender distribution was recruited from the
same sociodemographic environment. Exclusion criteria for controls included history of men-
tal disorder or prescription of any psychoactive medication, and history of severe mental disor-
der in a first-degree relative. Additional exclusion criteria for both groups were: brain injury,
neurological disease and substance abuse or dependence. All subjects gave written informed
consent after a full explanation of the study. The study was approved by the Institutional Re-
view Board of Parc Sanitari Sant Joan de Déu and the Institutional Ethics Committee of Funda-
ció Sant Joan de Déu. Clinical assessments and blood sample collection were performed within
two weeks after discharge. All patients, with the exception of one, were undergoing medication
with second-generation antipsychotic drugs at the time of the blood draw. The distribution of
antipsychotic treatment was as follows: 57.14% (n = 8) olanzapine, 21.43% (n = 3) risperidone,
14.29% (n = 2) aripiprazole, 14.29% (n = 2) quetiapine. 64.29% (n = 9) of the patients were also
treated with mood stabilizers: 46.86% (n = 6) lithium or 21.43% (n = 3) valproic acid.
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Peripheral blood mononuclear cell samples
Peripheral blood mononuclear cells (PBMC) were obtained as described [19]. 30 ml blood was
collected in EDTA tubes. PBMC were immediately isolated by Ficoll-Paque gradient method
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Briefly, 6 ml of blood sample were added
to 6 ml of Ficoll-Paque reagent and centrifuged at 2000 g for 30 minutes without brake. The
PBMC intermediate cell layer was collected and washed with RPMI medium (Invitrogen, Pais-
ley, UK). The isolated cells were immediately frozen in liquid nitrogen for protein lysates. Sam-
ples were immediately stored at -80°C.
Cell culture and treatments
Cerebellar granule neurons were obtained from P6 rats (Charles River Laboratories Inc., Wil-
mington, MA, USA) and cultured in 25mM KCl as previously described [25]. All protocols re-
garding the use of animals were approved by the Committee for the Humane Use of Animals
at Tufts University School of Medicine. At DIV 4–5, cells were treated for two hours with
serum-free media containing 25mM KCl and the following: lithium chloride (Sigma, St Louis,
MO, USA), sodium valproate (Sigma), or olanzapine (Sigma), and protein was analyzed by
Western blot.
Immunoblotting
Protein lysates from human PBMC were extracted as described [19]. 30 μg from the same
human protein lysates analyzed in our previous report [19] were analyzed in a blinded manner.
Cerebellar granule neurons were lysed in RIPA buffer supplemented with protease inhibitors
(Roche Molecular Biochemicals, Indianapolis, IN, USA) and phosphatase inhibitors (Santa
Cruz Technology, Santa Cruz, CA, USA). Equal amount of total protein extracts were resolved
by SDS⁄PAGE electrophoresis and immunoblotted with the indicated antibodies: pSP4 (specifi-
cally recognizes S770 phosphorylated Sp4) [17], SP4 (Santa Cruz Technology), pTauS396 (Cell
Signaling Technologies, Beverly, MA, USA), mitogen-activated protein kinase (MAPK) p42/44
(Cell Signaling Technologies), phospho glycogen synthase kinase 3 beta (GSK3β) S9 (Cell Sig-
naling Technologies), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Millipore Cor-
poration, Bedford, MA, USA) and β-actin (Sigma). Linear range exposures were quantified by
densitometry using Quantity One software (BioRad) in duplicate samples for human studies or
Fiji software for cerebellar granule neuron experiments.
For human samples, four independent western blots were prepared with the same amounts
of the same protein extracts for each human subject; immunostaining for pSP4 and total SP4
were detected in two blots each and normalized to β-actin values from the same membrane.
We calculated pSP4/SP4 ratio by referring the mean values of pSP4 immunoreactivity from
two independent immunoblot analyses to the mean values of total SP4 immunoreactivity from
other two independent immunoblot analyses. Both pSP4 and total SP4, normalized to β-actin,
were referred to a standard sample to allow comparison of relative levels between different sets
of samples and between repetitions. Total levels of SP4 were reported in [19]. The coefficient of
variation of β-actin immunoreactivities for pSP4 analysis, SP4 analysis and between both anal-
ysis were calculated and validate this method of normalization (pSP4 immunoblot analysis:
mean = 0.07, percentile 75th = 0.08, minimum and maximum [0.01, 0.21]; SP4 immunoblot
analysis: mean = 0.06; percentile 75th = 0.12; minimum and maximum [0.01, 0.28]; between
both analysis: mean = 0.06; Percentile 75th = 0.10; minimum and maximum [0.01, 0.21]). For
cerebellar granule neuron experiments, pSP4 and SP4 values from the same protein extracts
were determined; SP4 values were normalized to GAPDH and phospho-SP4/total SP4 ratio
was calculated and normalized to untreated, control, conditions.
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Statistical Analysis
For the analysis of PBMC samples from first-episode psychosis and control subjects D’Agos-
tino & Pearson omnibus normality test was carried out to test whether the variables followed a
normal distribution. Outliers were detected where indicated using Pierce’s criterion (as simpli-
fied by Gould) [26]. Non parametric Mann-Whitney test for quantitative variables or Chi-
Square test (χ2-test) for categorical variables were used to compare FEP and control groups,
and FEP treatment subgroups. Bivariate analyses were carried out to detect association of our
variables with potential confounding factors (age, gender, college education, duration of the ill-
ness and daily antipsychotic dose), using Mann–Whitney test for two groups, and Spearman or
Pearson correlation for non parametric and parametric quantitative variables. For studies of
treatment effect on pSP4/SP4 in cerebellar granule neuron cultures, all results represent the
mean ± SEM from at least 3 independent experiments. ANOVA followed by Bonferroni’s post
hoc test for multiple comparisons were performed where indicated. Statistical analysis was per-
formed with GraphPad Prism version 5.00 and SPSS 17. All statistical tests were two-tailed ex-
cept where otherwise indicated and significance level was set to 0.05.
Results
Demographic and clinical characteristics
The demographic and clinical characteristics for healthy subjects and patients with first-epi-
sode psychosis were previously reported [19] and are summarised in Table 1. The total sample
of patients did not show any significant differences from the healthy control group in sociode-
mographic variables, with the exception of college education, that was more frequent in control
group (Table 1) [19]. Clinical scores for CDS and YMRS scales showed significant differences
between patients and controls (Table 1). Further, a subgroup analysis of FEP group according
to the presence of lithium treatment did not show any significant differences in sociodemo-
graphic or clinical variables between subgroups (Table 1).
Phospho-SP4 S770 immunoreactivity is increased in peripheral blood
mononuclear cells of patients with first-episode psychosis
We determined SP4 S770 phosphorylation levels in protein lysates from PBMC of 14 FEP sub-
jects and 14 matched healthy controls (Table 1). We calculated pSP4/SP4 ratio in these samples
by referring SP4 phosphorylation levels to total SP4 immunoreactivity as determined in the
same protein extracts reported in our previous study [19]. Both pSP4 and total SP4 were inde-
pendently normalized to actin and a reference sample as indicated in the methods section. One
sample had to be excluded from the analysis due to low detection for both SP4 and pSP4 in the
FEP group (n = 13), however the statistical power for the remaining samples was 0.91 for a
two-tailed test which is over the standard threshold of 0.80. We observed that the ratio of
pSP4/SP4 was significantly increased in FEP subjects [U = 56.00; p = 0.047; median (IQR): con-
trol = 0.70 (0.07–1.72), FEP = 1.48 (0.17–3.82)] (Fig 1A and 1B and S1 Fig). The greater disper-
sion observed in FEP group suggested that other factors may be influencing pSP4/SP4 in these
patients. We searched for a possible correlation of the ratio of phosphorylated SP4 to the total
abundance of SP4 protein. pSP4/SP4 did not significantly correlate with total SP4 immunore-
activity (Spearman’s r = -0.230; 95% confidence interval = -0.596, 0.176; p = 0.250).
We further searched for an effect of lithium treatment on SP4 phosphorylation in these pa-
tients. We divided the FEP group into two treatment subgroups according to the presence or
absence of lithium treatment. We found significantly reduced levels of pSP4/SP4 ratio in the
lithium treated FEP group compared to the lithium untreated FEP group [U = 2.00; p = 0.0101;
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median (IQR): lithium untreated FEP group = 2.38(1.11–4.35); lithium treated FEP
group = 0.17 (0.10–0.83)], (Fig 1C). In contrast, analysis of SP4 immunoreactivity revealed no
significant differences when segregating FEP subjects by lithium treatment [U = 10.00,
p = 0.268; median (IQR): lithium treated FEP group = 0.44 (0.30–0.90); and FEP without lithi-
um treatment = 0.80 (0.65–1.07)] (Fig 1D).
We also investigated whether pSP4/SP4 ratio associated with the degree of severity mea-
sured by PANSS, CDS and YMRS scales in FEP patients. We found that pSP4/SP4 ratio did not
correlate with the scores of any scale (Total PANSS: Spearman r = -0.199; 95% confidence in-
terval = -0.670, 0.386; p = 0.496. Total CDS: Pearson r = -0.047; 95% confidence interval =
-0.564, 0.496; p = 0.872. Total YMRS: Pearson r = -0.099; 95% confidence interval = -0.599,
0.455; p = 0.736), suggesting that the observed increase in pSP4/SP4 is not influenced by
symptom severity.
We analyzed the influence of other demographic variables such as age and gender on the
ratio of pSP4/SP4 in the control-FEP comparison, and in an intragroup analysis of FEP subjects
designed to control for possible effects on pSP4/SP4 ratio of duration of the illness and daily
antipsychotic dose. This analysis showed that pSP4/SP4 ratio is not significantly associated
with any of the potential confounding factors (Table 2).
Table 1. Demographic and clinical features of cases (n = 28).
Controls (n = 14) FEP patients (n = 14) Statistics pvalue
Age (years) 25.6 ± 5.2 25.2 ± 5.5 91.00a 0.765
Gender (male) 50.00% (n = 7) 50.00% (n = 7) 0.00; 1b 1.000
College education 78.6% (n = 11) 35.7% (n = 5) 5.25; 1b 0.022
Duration of illness (days) N/A 81.3 ± 51.3 N/A N/A
Daily APdc (mg/day) N/A 358.3 ± 170.3 N/A N/A
Treatment N/A N/A N/A
Antipsychotics 92.86% (n = 13)
Antipsychotics + Li 42.86% (n = 6)
Antipsychotics + VA 21.43%(n = 3)
PANSS total score N/A 77.0 ± 10.4 N/A N/A
CDS total score 0.5 ± 1.4 5.4 ± 5.0 31.00a 0.001
YMRS total score 11.5 ± 1.2 14.6 ± 2.4 21.00a 0.000
Lithium untreated FEP(n = 8) Lithium treated FEP (n = 6) Statistics pvalue
Age (years) 23.9 ± 3.4 27.0 ± 7.5 19.00a 0.573
Gender (male) 62.50% (n = 5) 33.33% (n = 2) 1.17; 1b 0.280
College education 37.5% (n = 3) 33.33% (n = 2) 0.26; 1b 0.872
Duration of illness (days) 73.38 ± 59.50 91.83 ± 40.77 17.00a 0.401
Daily APdc (mg/day) 300.0 ± 173.7 436.1 ± 143.1 12.50a 0.152
PANSS total score 78.5 ± 12.8 75.0 ± 6.3 22.50a 0.897
CDS total score 5.09 ± 6.2 4.7 ± 3.4 22.50a 0.897
YMRS total score 15.0 ± 2.7 14.0 ± 1.9 19.00a 0.559
Adapted from [19]. Mean ± standard deviation or relative frequency are shown for each variable; FEP, ﬁrst-episode psychosis; APd, antipsychotic dose;
PANSS, Positive and Negative Syndrome Scale; CDS, Calgary Depression Scale; YMRS, Young Mania Rating Scale; Li, lithium; VA, valproic acid; N/A,
not applicable.
a Mann-Whitney U is shown for non-parametric variables.
b χ2 and degrees of freedom are shown for qualitative variables.
c Chlorpromazine equivalent dose was calculated based on the electronic records of drug prescriptions of the patients [29].
doi:10.1371/journal.pone.0125115.t001
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Lithium reduces the levels of phospho-SP4 S770 in rat cultured
cerebellar granule neurons
To further explore the effect of lithium and other drugs prescribed in the FEP cohort on SP4
phosphorylation, we used rat primary cultured cerebellar granule neurons as an in vitro cell
model. We tested if lithium chloride, valproic acid or olanzapine, the most frequently pre-
scribed antipsychotic in our cohort, influenced the levels of SP4 S770 phosphorylation in cul-
tured cerebellar granule neurons. We found that only treatment with lithium chloride
significantly decreased pSP4/SP4 ratio (ANOVA: F = 20.4; df = 3, 8; p = 0.0004) (Fig 2A and S2
Fig); while pSP4/SP4 ratio was not influenced by valproic acid (ANOVA: F = 2.60; df = 3, 12;
p = 0.101) or olanzapine (ANOVA: F = 1.771; df = 3, 8; p = 0.230) in cultured neurons (Fig 2B
and 2C and S2 Fig).
Discussion
Our study shows that phosphorylation of transcription factor SP4 at S770 is increased in
peripheral blood mononuclear cells of first-episode psychosis patients, that lithium-treated
patients have reduced SP4 phosphorylation levels and that lithium suppresses SP4 phos-
phorylation in an in vitro cell model. Thus, our findings suggest that SP4 phosphorylation
isa potential biomarker for first-episode psychosis which may be regulated by lithium
treatment.
Our data adds further evidence for a role for SP4 phosphorylation at S770 in the post-trans-
lational regulation of SP4 in the context of psychiatric disorders. An increasing body of evi-
dence indicates that SP4 transcription factor has a role in complex psychotic disorders through
its regulation of a large network of genes, including components of NMDAR signaling path-
ways [8, 11–13, 19, 27, 28]. In line with these studies, we have described alterations of SP4 in
the postmortem brain of psychotic patients which supports a role for SP4 in these disorders. In
particular, we have shown reduced immunoreactivity of SP4 in the postmortem cerebellum
and prefrontal cortex of subjects with bipolar disorder [11]; a negative association of SP4
immunoreactivity with negative symptom severity in the cerebellum of patients with schizo-
phrenia [12]; and altered SP4 levels in the postmortem hippocampus of subjects with
Fig 1. Phospho-SP4 S770 is increased in peripheral blood mononuclear cells of patients with first-
episode psychosis compared to control subjects and this increase is not present in those patients
with lithium prescription. Immunoreactivity of phospho-SP4 S770, SP4 and β-actin was determined in the
same protein extracts from peripheral blood mononuclear cells (PBMC) of control (C, n = 14), and first-
episode psychosis (FEP, n = 14) individuals. The resultant bands were quantified by densitometry. Both
phospho-SP4 (pSP4) and SP4 were normalized to β-actin values and referred to a standard sample in two
independent immunoblot analysis for pSP4 and SP4. pSP4/SP4 ratio was calculated for these samples by
referring the mean normalized phospho-SP4 immunoreactivity levels to the mean normalized total SP4
immunoreactivity. Final pSP4/SP4 values were normalized to the mean of control group. Levels of total SP4
immunoreactivity normalized to β-actin were reported previously [19]. (A) Images show representative pSP4,
SP4, and β-actin immunoblots from four control individuals and four FEP subjects. Patients FEP2 and FEP4
were both receiving lithium treatment. (B) The graph shows the mean and standard deviation of the
normalized pSP4/SP4 ratio for control and FEP groups. Each value represents the mean of two independent
analyses. One sample in FEP group had to be excluded from the analysis due to almost undetectable levels
of pSP4 and SP4 (n = 13). Statistical analysis was performed using one-tailed Mann-Whitney test. (C) The
graph shows the mean and standard deviation of normalized pSP4/SP4 ratio for FEP patients without lithium
treatment (Untreated, n = 7), and FEP patients with lithium treatment (Treated, n = 6). Each value represents
the mean of two independent analyses. An outlier was detected for pSP4/SP4 ratio in the lithium treated
group using the Peirce criterion and therefore excluded from the analysis (n = 5). Statistical analysis was
performed using two-tailed Mann-Whitney test. (D) The graph shows the mean and standard deviation of
normalized total SP4 immunoreactivity for FEP patients without lithium treatment, and FEP patients with
lithium treatment. Each value represents the mean of two independent analyses. Statistical analysis was
performed using two-tailed Mann-Whitney test. (*p<0.05; n.s., not significant).
doi:10.1371/journal.pone.0125115.g001
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schizophrenia and in a mouse model of acute psychosis [13]. We also recently reported that
lower SP4 immunoreactivity in first-episode psychosis patients correlates positively with right
hippocampal volume, measured by voxel-based morphometric analysis on brain structural
magnetic resonance images [20]. Most relevant to the work described here, we have observed
that SP4 phosphorylation at S770 inversely associated with SP4 immunoreactivity in human
postmortem cerebellum [18] and this phosphorylation is increased in this region in bipolar dis-
order patients and in schizophrenia patients with more severe negative symptoms, which both
showed reduced SP4 immunoreactivity [11, 12]. Here we report that SP4 S770 phosphorylation
is increased in peripheral lymphocytes of first-episode psychosis. In this context, however, we
observed that SP4 phosphorylation did not correlate with total SP4 immunoreactivity. This is
similar to the effect of NMDAR inhibition in cultured neurons, which increased SP4 S770
phosphorylation and inhibited Sp4 function, without an effect on total SP4 immunoreactivity
[17]. Thus, increased SP4 phosphorylation in lymphocytes of FEP may reflect alterations in up-
stream signaling pathways that control SP4 functions.
Lithium has been successfully used as a mood stabilizer for the treatment of bipolar disorder
for decades, and, to date, remains the most efficient drug for long-term preventive treatment
Table 2. Influence of demographic and clinical characteristics on pSP4/SP4 ratio in peripheral blood
mononuclear cells in first-episode psychosis and control subjects.
pSP4/SP4 ratio
FEP-C cohort FEP cohort
Age
Spearman r -0.091 -0.483
95% CI (-0.465, 0.310) (-0.833, 0.146)
p value 0.652 0.112
Gender
Male (Mean ± SD) 1.68 ± 2.09 2.74 ± 2.55
Female (Mean ± SD) 1.48 ± 1.83 0.74 ± 0.86
U 89.00 8.00
p value 0.942 0.149
College education
No (Mean ± SD) 1.90 ± 2.24 1.90 ± 2.46
Yes (Mean ± SD) 1.34 ± 1.69 2.95 ± 2.42
U 69.00 13.00
p value 0.317 0.504
Duration of illnessa N/A
Spearman r 0.095
95% CI (-0.521, 0.646)
p value 0.770
Daily APda,b N/A
Spearman r -0.269
95% CI (-0.739, 0.378)
p value 0.399
FEP, ﬁrst-episode psychosis; C, control; CI. conﬁdence interval; SD, standard deviation; U, Mann-Whitney
U; APd, antipsychotic dose; N/A, not applicable.
a Analysis in ﬁrst-episode psychosis group only.
b Daily Chlorpromazine equivalent dose.
doi:10.1371/journal.pone.0125115.t002
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[22, 24]. In our study, we found that FEP patients that had received lithium treatment exhibited
reduced SP4 S770 phosphorylation in lymphocytes when compared to FEP patients that had
not received lithium and that lithium treatment in vitro suppressed SP4 phosphorylation in
cultured rat cerebellar granule neurons. This preliminary finding that lithium seems to inhibit
SP4 phosphorylation in patients may suggest that this phosphorylation could be a readout
Fig 2. SP4 phosphorylation at S770 is reduced by lithium chloride treatment. A. Cerebellar granule neurons were treated with serum-free media
containing 25mM KCl for two hours in the presence of the indicated concentrations of lithium chloride (A), valproic acid (VPA) (B) or olanzapine (OLZ) (C).
14 μg (A) or 5 μg (B and C) of a total protein extracts were analyzed byWestern blot using antisera to phospho-SP4 S770, total SP4, phospho-GSK3β S9 (a
positive control for lithium treatment) (A), phospho-Tau S396 (a positive control for VPA) (B), p42/44 MAPK (a positive control for OLZ) (C) and GAPDH as a
loading control. The graphs show the densitometric quantification of S770 phosphorylated SP4 relative to the levels of total SP4. Statistical analysis was
performed using ANOVA followed by Bonferroni’s post hoc comparison between untreated condition and the different doses of drugs. N = 3 (**p<0.01).
doi:10.1371/journal.pone.0125115.g002
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measure of the treatment. However, further studies are needed to propose this phosphorylation
as a marker for treatment effectiveness and a possible therapeutic target in psychotic patients.
In addition, since these patients were treated with other drugs, it remains possible that the ob-
served reduction in pSP4 in this subset of patients could be due to other treatments. However,
our analysis in rat cerebellar granule neurons supports the idea that lithium may be responsible
for the reduction of pSP4 in patients, and not olanzapine, the most prevalent prescribed anti-
psychotic in this cohort. Future studies are needed to fully explore the effect of other treatments
on this phosphorylation in blood cells.
In peripheral lymphocytes from patients, total SP4 immunoreactivity was not significantly
affected by lithium treatment, suggesting that the pathways regulating SP4 phosphorylation
and protein abundance are independent in human lymphocytes. In contrast, we previously re-
ported that, in cerebellar granule neurons, lithium partially stabilized SP4 protein, leading to
significantly increased protein levels in non-depolarizing conditions [11]. Thus our data sug-
gests that, in cerebellar granule neurons, lithium impacts pathways that regulate both SP4 sta-
bility and phosphorylation at S770, consistent with the view that these pathways are coupled in
some contexts. Identifying these pathways is a future goal for better understanding the signal-
ing pathways regulating SP4 and their possible contribution to the pathophysiology and thera-
py of psychiatric disorders.
Analysis of biological parameters in first-episode psychosis is helpful to identify altered
players that could be involved in the etiopathogenesis of psychotic disorders in the early stages.
We have recently described an increase in SP4 phosphorylation in the postmortem cerebellum
of bipolar disorder and schizophrenia patients [18]. The finding that the pSP4/SP4 ratio is in-
creased in FEP and can also be observed in the cerebellum in a much later stage of the disease,
supports the possibility that this modification in PBMC could be a readout of SP4 alteration oc-
curring in the brain in the early stages of the disease. However, we cannot rule out the possibili-
ty that SP4 S770 phosphorylation may be dynamic and could change over the course of the
disease in PBMC, as we also cannot predict how peripheral levels of phosphorylated SP4 relate
to the actual levels in the different brain areas involved in psychosis.
A few limitations need to be acknowledged. The sample size analysed here is small and the
findings require replication in a larger sample of healthy subjects and FEP patients treated and
untreated with lithium. In addition, our first-episode psychosis cohort is not drug naïve since
the patients had been receiving antipsychotic treatment. Nevertheless, treatment duration was
shorter than 6 months in all cases, and our statistical analysis did not show a correlation of SP4
phosphorylation with the daily dose of antipsychotics suggesting that these treatments may not
influence our results. Moreover, our study of treatment effect on SP4 phosphorylation in cul-
tured rat cerebellar neurons showed that SP4 phosphorylation levels were not affected by in
vitro treatment with the antipsychotic olanzapine, the most representative antipsychotic in our
cohort (n = 8). Despite these limitations, findings from this study may contribute towards a
better understanding of the molecular mechanisms that underlie psychosis. Peripheral blood
screening of SP4 phosphorylation levels may be a useful peripheral biomarker of psychosis and
potentially regulated by lithium treatment in the early stages of psychosis.
Supporting Information
S1 Fig. Phospho-SP4 S770 is increased in peripheral blood mononuclear cells of patients
with first-episode psychosis compared to control subjects. Immunoreactivity of phospho-
SP4 S770 (pSP4), SP4 and β-actin was determined in the same protein extracts from peripheral
blood mononuclear cells (PBMC) of control (C, n = 14), and first-episode psychosis (FEP,
n = 14) individuals as previously reported [19]. Images show full size representative
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immunoblots from phospho-SP4 S770 (A), total SP4 (B) and β-actin (A and B) immunoreac-
tivity. N/A, not applicable.
(TIF)
S2 Fig. SP4 phosphorylation at S770 is reduced by lithium chloride treatment. Cerebellar
granule neurons were treated with serum-free media containing 25mM KCl for two hours in
the presence of the indicated concentrations of lithium chloride (A), valproic acid (VPA) (B)
or olanzapine (OLZ) (C). Images show full size immunoblots from phospho-SP4 S770, total
SP4, phospho-GSK3β S9 (a positive control for lithium treatment), phospho-Tau S396 (a posi-
tive control for VPA) (B), p42/44 MAPK (a positive control for OLZ) (C) and GAPDH immu-
noreactivity.
(TIF)
S1 Table. Detailed demographic, clinical features and molecular measures of cases. FEP,
first-episode psychosis; APd, antipsychotic dose; PANSS, Positive and Negative Syndrome
Scale; CDS, Calgary Depression Scale; YMRS, Young Mania Rating Scale; ARP, aripripazole;
QTP, quetiapine; Li, lithium; OLZ, olanzapine; RS, risperidone; VA, valproic acid; N/A, not ap-
plicable.
(XLSX)
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